2022
DOI: 10.3390/molecules27123686
|View full text |Cite
|
Sign up to set email alerts
|

TP-CSO: A Triptolide Prodrug for Pancreatic Cancer Treatment

Abstract: Triptolide (TP) is a potential drug candidate for the treatment of cancer, but its use was hampered by its systemic toxicity and poor water solubility. Hence, a TP-CSO prodrug was synthesized by conjugating TP to chitosan oligosaccharide (CSO), and characterized by 1H NMR, FTIR, DSC and XRD analyses. The TP-CSO containing about 4 wt% of TP exhibited excellent water solubility (15 mg/mL) compared to TP (0.017 mg/mL). Compared with TP, the pharmacokinetics of the conjugate after oral administration showed a thre… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 25 publications
0
1
0
Order By: Relevance
“…It can also be modified as prodrug. Chitosan oligosaccharide (CSO) conjugated triptolide could improve the water solubility to 15 mg/ml) ( Wang et al, 2022b ). Triptolide could also be conjugated with 2-(pyridin-2-yldisul-fanyl)ethyl acrylate (PDA)- poly (ethylene glycol) methyl (PEG) and lactobionic acid (LBA) ( Sui et al, 2021 ).…”
Section: Natural Products Undergoing Clinical Evaluation In Pancreati...mentioning
confidence: 99%
“…It can also be modified as prodrug. Chitosan oligosaccharide (CSO) conjugated triptolide could improve the water solubility to 15 mg/ml) ( Wang et al, 2022b ). Triptolide could also be conjugated with 2-(pyridin-2-yldisul-fanyl)ethyl acrylate (PDA)- poly (ethylene glycol) methyl (PEG) and lactobionic acid (LBA) ( Sui et al, 2021 ).…”
Section: Natural Products Undergoing Clinical Evaluation In Pancreati...mentioning
confidence: 99%